Last year was a forgettable one for DaVita (NYSE: DVA) shareholders, but understandably so. The stock ended up losing 25% of its value in calendar 2025 due to a combination of a declining number of dialysis patients, subpar guidance for most of the year, uncertainty as to how much insurers were willing to continue reimbursing the company, and an embarrassing ransomware attack reported in April. It's just possible, however, that the sellers overshot their target. As of 12:16 p.m. ET Tuesday, DaVita stock ...

DaVita Inc. (NYSE: DVA) stock surged on Tuesday after the company reported upbeat fourth-quarter earnings and fiscal 2026 guidance.Earnings SummaryThe kidney care provider reported adjusted earnings of $3.40 per share, beating the consensus of $3.16.Sales came in at $3.62 billion, up 5.8% year over year, beating the consensus of $3.497 billion.Revenue per treatment jumped from $410.59 to $422.60.The quarter change was primarily driven by increases in average reimbursement rates and other normal fluctuations ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.The Dow traded down 0.19% to 49,316.23 while the NASDAQ dipped 1.23% to 23,302.18. The S&P 500 also fell, dropping, 0.62% to 6,933.29.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsMaterials shares gained by 1.8% on Tuesday.In trading on Tuesday, information technology stocks fell by 1.9%.Top HeadlineOn Tuesday, Pfizer Inc. (NYSE:PFE) sh ...

Key Takeaways DVA posted Q4 adjusted EPS of $3.40 and revenue of $3.62 billion, both beating the Zacks Consensus Estimate.DaVita expanded gross margin by 98 bps to 33.4% and lifted adjusted operating margin to 20.4% in Q4.DVA issued 2026 adjusted EPS guidance of $13.60 to $15.00 and expects RPT growth of 1% to 2%.DaVita Inc. (DVA) delivered adjusted earnings per share (EPS) from continuing operations of $3.40 in the fourth quarter of 2025, up 51.8% year over year. The figure surpassed the Zacks Consensus Es ...

DaVita posts adjusted beats earnings expectations and posts 9.9% revenue growth in the third quarter. ...

分组1: Pterodine - Pterodine reported better-than-expected quarterly results, with adjusted EPS at $1.80 and revenue at $1.08 billion, surpassing street expectations [2][4] - The company experienced its first billion-dollar quarter since 2021, indicating a significant cyclical structural rebound [4] - Guidance for Q1 revenue is projected between $1.15 billion and $1.4 billion, with EPS guidance between $1.89 and $2.25, both exceeding market expectations [5][4] - Pterodine is recognized as a core player in the AI sector, benefiting from increased demand for AI-related chips across various applications [3][6] 分组2: Dvita - Dvita's quarterly results showed strong performance with adjusted EPS of $3.40 and revenue of $3.62 billion, both exceeding street forecasts [8][9] - The company anticipates a bullish outlook for 2026, with adjusted EPS guidance between $13.60 and $15.00, reflecting confidence in reimbursement trends and operational momentum [8][9] - Dvita's results were supported by steady demand for kidney dialysis services and improved reimbursement rates, although they are still addressing operational challenges from a ransomware attack [9][10] 分组3: Pepsi - Pepsi reported adjusted EPS of $2.26 and revenue of $29.34 billion, both beating market expectations [12] - The company is experiencing volume softness in North America, with global food volume declining by 2%, while beverage volume increased by 1% [12][13] - Pepsi is implementing a pricing strategy shift, including planned price cuts, and expanding into protein-based snacks and functional drinks to meet changing consumer demands [13][14]

Analyst’s Disclosure: I/we have a beneficial long position in the shares of DVA, FMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial a ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of DVA, FMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial a ...

（文章来源：每日经济新闻） 每经AI快讯，2月3日，达维塔（DaVita）公司股价上涨17.8%。 ...

DaVita Inc. (NYSE:DVA) reported an EPS of $3.40, beating the estimated $3.24 and showcasing a significant year-over-year improvement.The company's revenue reached $3.62 billion for the quarter, exceeding consensus estimates and indicating robust demand for its kidney dialysis services.DaVita's financial metrics, including a P/E ratio of 10.38 and a current ratio of 1.36, highlight its strong market position and operational efficiency.DaVita Inc. (NYSE:DVA), a prominent player in the healthcare sector, speci ...